Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease

CONCLUSION: Lecanemab is a humanized monoclonal antibody that is selective for soluble amyloid-beta (Aβ) aggregates. Lecanemab has exhibited a decrease in brain Aβ plaques and moderately less decline on clinical measures of cognitive function.PMID:38095619 | DOI:10.1177/10600280231218253

Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Juliane Park Carson Simpson Katie Patel Source Type: research